Ozempic

Country: Evrópusambandið

Tungumál: enska

Heimild: EMA (European Medicines Agency)

Kauptu það núna

Vara einkenni Vara einkenni (SPC)
03-05-2023
Opinber matsskýrsla Opinber matsskýrsla (PAR)
21-02-2018

Virkt innihaldsefni:

semaglutide

Fáanlegur frá:

Novo Nordisk A/S

ATC númer:

A10BJ06

INN (Alþjóðlegt nafn):

semaglutide

Meðferðarhópur:

Drugs used in diabetes

Lækningarsvæði:

Diabetes Mellitus

Ábendingar:

Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Vörulýsing:

Revision: 10

Leyfisstaða:

Authorised

Leyfisdagur:

2018-02-08

Upplýsingar fylgiseðill

                                45
B. PACKAGE LEAFLET
46
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
OZEMPIC 0.25 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
semaglutide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
–
Keep this leaflet. You may need to read it again.
–
If you have any further questions, ask your doctor, pharmacist or
nurse.
–
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
–
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Ozempic is and what it is used for
2.
What you need to know before you use Ozempic
3.
How to use Ozempic
4.
Possible side effects
5.
How to store Ozempic
6.
Contents of the pack and other information
1.
WHAT OZEMPIC IS AND WHAT IT IS USED FOR
Ozempic contains the active substance semaglutide. It
_ _
helps your body reduce your blood sugar level
only when blood sugar is too high and can help prevent heart disease.
Ozempic is used to treat adults (aged 18 years and older) with type 2
diabetes when diet and exercise
is not enough:
•
on its own – when you cannot use metformin (another diabetes
medicine) or
•
with other medicines for diabetes – when they are not enough to
control your blood sugar levels.
These may be medicines you take by mouth or inject such as insulin.
It is important that you continue with your diet and exercise plan as
told by your doctor, pharmacist or
nurse.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE OZEMPIC
_ _
DO NOT USE OZEMPIC
•
if you are allergic to semaglutide or any of the other ingredients of
this medicine (listed in
section 6).
WARNINGS AND PRECAUTIONS
Talk to your doctor, pharmacist or nurse before using this medicine.
This medicine is not the same as insulin and you should not use it if:
•
you have type 1 diabetes – a condition where your body does no
                                
                                Lestu allt skjalið
                                
                            

Vara einkenni

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Ozempic 0.25 mg solution for injection in pre-filled pen
Ozempic 0.5 mg solution for injection in pre-filled pen
Ozempic 1 mg solution for injection in pre-filled pen
Ozempic 2 mg solution for injection in pre-filled pen
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Ozempic 0.25 mg
solution for injection
One ml of solution contains 1.34 mg of semaglutide*. One pre-filled
pen contains 2 mg semaglutide*
in 1.5 ml solution. Each dose contains 0.25 mg of semaglutide in 0.19
ml solution.
Ozempic 0.5 mg solution for injection
One ml of solution contains 1.34 mg of semaglutide*. One pre-filled
pen contains 2 mg semaglutide*
in 1.5 ml solution. Each dose contains 0.5 mg of semaglutide in 0.37
ml solution.
Ozempic 1 mg solution for injection
One ml of solution contains 1.34 mg of semaglutide*. One pre-filled
pen contains 4 mg semaglutide*
in 3 ml solution. Each dose contains 1 mg of semaglutide in 0.74 ml
solution.
Ozempic 2 mg solution for injection
One ml of solution contains 2.68 mg of semaglutide*. One pre-filled
pen contains 8 mg semaglutide*
in 3 ml solution. Each dose contains 2 mg of semaglutide in 0.74 ml
solution.
*Human glucagon-like peptide-1 (GLP-1) analogue produced in
_Saccharomyces cerevisiae _
cells
_ _
by
_ _
recombinant DNA technology
_._
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection (injection).
Clear and colourless or almost colourless, isotonic solution; pH=7.4.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Ozempic is indicated for the treatment of adults with insufficiently
controlled type 2 diabetes mellitus
as an adjunct to diet and exercise
•
as monotherapy when metformin is considered inappropriate due to
intolerance or
contraindications
•
in addition to other medicinal products for the treatment of diabetes.
3
For trial results with respect to combinations, effects on glycaemic
control and cardiovascular events,
and the populations studied, see sections 4.4, 
                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Upplýsingar fylgiseðill Upplýsingar fylgiseðill búlgarska 03-05-2023
Vara einkenni Vara einkenni búlgarska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla búlgarska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill spænska 03-05-2023
Vara einkenni Vara einkenni spænska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla spænska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill tékkneska 03-05-2023
Vara einkenni Vara einkenni tékkneska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla tékkneska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill danska 03-05-2023
Vara einkenni Vara einkenni danska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla danska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill þýska 03-05-2023
Vara einkenni Vara einkenni þýska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla þýska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill eistneska 03-05-2023
Vara einkenni Vara einkenni eistneska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla eistneska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill gríska 03-05-2023
Vara einkenni Vara einkenni gríska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla gríska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill franska 03-05-2023
Vara einkenni Vara einkenni franska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla franska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ítalska 03-05-2023
Vara einkenni Vara einkenni ítalska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla ítalska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill lettneska 03-05-2023
Vara einkenni Vara einkenni lettneska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla lettneska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill litháíska 03-05-2023
Vara einkenni Vara einkenni litháíska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla litháíska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ungverska 03-05-2023
Vara einkenni Vara einkenni ungverska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla ungverska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill maltneska 03-05-2023
Vara einkenni Vara einkenni maltneska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla maltneska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill hollenska 03-05-2023
Vara einkenni Vara einkenni hollenska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla hollenska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill pólska 03-05-2023
Vara einkenni Vara einkenni pólska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla pólska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill portúgalska 03-05-2023
Vara einkenni Vara einkenni portúgalska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla portúgalska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill rúmenska 03-05-2023
Vara einkenni Vara einkenni rúmenska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla rúmenska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvakíska 03-05-2023
Vara einkenni Vara einkenni slóvakíska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla slóvakíska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvenska 03-05-2023
Vara einkenni Vara einkenni slóvenska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla slóvenska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill finnska 03-05-2023
Vara einkenni Vara einkenni finnska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla finnska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill sænska 03-05-2023
Vara einkenni Vara einkenni sænska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla sænska 21-02-2018
Upplýsingar fylgiseðill Upplýsingar fylgiseðill norska 03-05-2023
Vara einkenni Vara einkenni norska 03-05-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill íslenska 03-05-2023
Vara einkenni Vara einkenni íslenska 03-05-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill króatíska 03-05-2023
Vara einkenni Vara einkenni króatíska 03-05-2023
Opinber matsskýrsla Opinber matsskýrsla króatíska 21-02-2018

Leitaðu viðvaranir sem tengjast þessari vöru

Skoða skjalasögu